Share-based Payment Arrangement, Expense of Ovid Therapeutics Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ovid Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,108,000, a 15% decline year-over-year.
  • Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,871,000, a 28% decline year-over-year.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,276,000, a 14% decline from 2023.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,285,000, a 11% increase from 2022.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,556,686, a 30% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Ovid Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,871,000 $1,108,000 -$200,000 -15% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $5,071,000 $1,219,000 -$521,000 -30% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $5,592,000 $1,284,000 -$684,000 -35% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $6,276,000 $1,260,000 -$530,000 -30% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $6,806,000 $1,308,000 -$323,000 -20% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $7,129,000 $1,740,000 -$208,000 -11% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $7,337,000 $1,968,000 +$52,000 +2.7% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $7,285,000 $1,790,000 +$60,386 +3.5% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $7,224,614 $1,631,000 -$151,043 -8.5% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $7,375,657 $1,948,000 +$227,783 +13% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $7,147,874 $1,916,000 +$591,188 +45% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $6,556,686 $1,729,614 +$414,415 +32% 01 Oct 2022 31 Dec 2022 10-K 08 Mar 2024 2023 FY
Q3 2022 $6,142,271 $1,782,043 +$620,132 +53% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $5,522,139 $1,720,217 +$462,872 +37% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $5,059,267 $1,324,812 +$4,810 +0.36% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $5,054,457 $1,315,199 -$735,652 -36% 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
Q3 2021 $5,790,109 $1,161,911 -$1,454,329 -56% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $7,244,438 $1,257,345 -$297,987 -19% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $7,542,425 $1,320,002 +$17,071 +1.3% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $7,525,354 $2,050,851 +$923,988 +82% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $6,601,366 $2,616,240 +$1,431,758 +121% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $5,169,608 $1,555,332 +$303,425 +24% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $4,866,183 $1,302,931 -$339,609 -21% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $5,205,792 $1,126,863 -$604,299 -35% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
Q3 2019 $5,810,091 $1,184,482 -$509,124 -30% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $6,319,215 $1,251,907 -$592,299 -32% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $6,911,514 $1,642,540 -$152,427 -8.5% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $7,063,941 $1,731,162 +$320,494 +23% 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q3 2018 $6,743,447 $1,693,606 +$318,060 +23% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $6,425,387 $1,844,206 -$348,682 -16% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $6,774,069 $1,794,967 +$376,313 +27% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $6,397,756 $1,410,668 +$362,089 +35% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q3 2017 $6,035,667 $1,375,546 +$280,385 +26% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $5,755,282 $2,192,888 +$1,416,157 +182% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $4,339,125 $1,418,654 +$697,659 +97% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $3,641,466 $1,048,579 01 Oct 2016 31 Dec 2016 10-K 29 Mar 2018 2017 FY
Q3 2016 $1,095,161 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $776,731 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $720,995 01 Jan 2016 31 Mar 2016 10-Q 13 Jun 2017 2017 Q1

Ovid Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,276,000 -$1,009,000 -14% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $7,285,000 +$728,314 +11% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $6,556,686 +$1,502,229 +30% 01 Jan 2022 31 Dec 2022 10-K 08 Mar 2024 2023 FY
2021 $5,054,457 -$2,470,897 -33% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
2020 $7,525,354 +$2,319,562 +45% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $5,205,792 -$1,858,149 -26% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
2018 $7,063,941 +$666,185 +10% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
2017 $6,397,756 +$2,756,290 +76% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
2016 $3,641,466 +$2,184,153 +150% 01 Jan 2016 31 Dec 2016 10-K 29 Mar 2018 2017 FY
2015 $1,457,313 01 Jan 2015 31 Dec 2015 10-K 29 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.